CubaseBio

Oblique Therapeutics is developing a new type of antibody-based medication for chronic pain and metastatic cancer. Oblique Therapeutics is an early stage innovation-driven pharmaceutical company aiming at developing transformative medicines against advanced and metastatic cancer.

Emulsi Biotech is a biotechnology company that develops lipid technology to deliver biologic drugs orally.

Our vision is to develop and bring to the market safe and effective treatments for women specific diseases and medical conditions.

OncoZenge is a Swedish pharmaceutical company. It develops better products for the supportive care of cancer patients.

Elicera Therapeutics is a clinical stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments.

Alligator Bioscience is an innovative research based biotech company focused on developing novel drugs for immunotherapy of cancer. Alligator discovers and develops drug development candidates up to phase IIa clinical studies. Alligator’s pipeline currently counts three immune-modulating projects, ADC-1013, ADC-1015, and ADC-1016. Alligator uses its proprietary technology platforms: ALLIGATOR-GOLD, a unique fully human antibody library, and FIND® (Fragment INduced Diversity), a powerful in vitro based antibody optimization technology, in growing our pipeline.

Moleculent is dedicated to creating tech-based products that utilize fresh knowledge about the molecular roots of human biology. Creating innovative products to improve human health is their driving force. They anticipate a significant advancement in our comprehension of the molecular underpinnings of human biology within the next decade, which will result in enhanced treatments, diagnostics, and a deeper understanding.

Bio-Works was established in 2006 and specializes in creating, producing, and distributing cutting-edge products for the purification and separation of proteins and other molecules. The team at Bio-Works has extensive experience in the biotech industry and in protein purification, and the company is based in Uppsala, Sweden, at the Klövern Business Park site.

Verigraft AB is a biotech company that creates personalized tissue-engineered transplants for use in regenerative medicine by converting donated allogeneic tissue into personalized tissue to prevent transplant rejection. Their unique technology platform involves a combination of decellularization and reconditioning/recellularization processes to individualize patient tissue. Verigraft's technology eliminates the need for lifelong immunosuppression. They aim to provide a life-changing impact to patients while benefiting hospitals, healthcare providers, and society on a global scale. Preclinical development and safety data from large animals have been completed for their personalized tissue-engineered vein (P-TEV) product, with plans for clinical development within the next six months.

Lipum aims to eliminate or alleviate painful symptoms for millions of patients suffering from chronic inflammatory diseases. Lipum has a biological anti-inflammatory drug candidate developed against Rheumatoid Arthritis (RA) – an autoimmune disease characterized by chronic inflammation of the joints. It often causes disability and lowers the quality of life for millions. Lipum also addresses the treatment of Juvenile Idiopathic Arthritis (JIA) that is a rare disease affecting children. A novel biological drug for this disease may be considered for an orphan drug designation. Treatment of other chronic inflammatory conditions is also explored. Related diseases are such as Crohn’s disease, ulcerative colitis, ankylosing spondylitis, and psoriatic arthritis. Lipum's biological anti-inflammatory drug candidate provides a novel mechanism of action. Therefore, it is assumed to have less adverse effects than current treatments in use.

ArgusEye is a biotech firm that offers sensor solutions for instant identification of biological systems and processes. Their sensor technology, which is patented and based on nanoplasmonic sensing with fiber optics, was developed through rigorous academic research. With the ability to incorporate tailored receptors, ArgusEye provides adaptable and highly sensitive sensing systems for a wide range of targets.

Sigrid Therapeutics is developing an ingested medical device for lowering blood sugar in prediabetics.